E4BP4 (NFIL3) Antibody, anti-human, REAfinity™
Synonyms: NFIL3
RECOMBINANT
Bioz Star90/100 Bioz rating
1 Citation4 Images
Clone:
REA732 | MABA223
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
ICFC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for E4BP4 (NFIL3) Antibody, anti-human, REAfinity™

Intracellular flow cytometry applications
APC
PE
Recommended dilution:
1:50
Remark:
The antibody is suited for staining of formaldehyde-fixed cells.
Data source:
Miltenyi Biotec
Conjugate:
APC
Used products:
130-111-249, 130-111-435
Description:
Human peripheral blood mononuclear cells (PBMCs) were either left unstimulated (left image) or stimulated with CD3/CD28 antibodies for 16 hours. Cells were fixed and permeabilized using the FoxP3 Staining Buffer Set. Cells were then stained with Anti-E4BP4 (NFIL3) antibodies as well as with CD20 antibodies and analyzed by flow cytometry using the the MACSQuant® Analyzer. Cell debris were excluded from the analysis based on scatter signals.

Application imageView details view details

Application imageView details view details
Specifications for E4BP4 (NFIL3) Antibody, anti-human, REAfinity™
Overview

Clone REA732 recognizes the human E4BP4 (NFIL3) antigen, a basic leucine zipper transcription factor that is regulated by the cytokine IL-3. E4BP4 is highly expressed in lung and in lower levels in brain and spinal cord. E4BP4 acts with members of the PAR family of transcription factors with which it shares DNA-binding specificity. It plays a role in commitment to cell survival versus apoptosis, anti-inflammatory response, and transcriptional controlling of the mammalian circadian clock. Furthermore, E4BP4 plays an essential role in the development of CD8α+ conventional dendritic cells (cDCs).

Additional information: Clone REA732 displays negligible binding to Fc receptors.

Alternative names

NFIL3

Detailed product information

Technical specifications

Clone
REA732
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (I), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
E4BP4 (NFIL3)
Molecular mass of antigen [kDa]
52
Distribution of antigen
other, bladder, bone marrow, lymph node, muscle, testicle, trachea
Entrez Gene ID
RRID
AB_2651591, AB_2651594, AB_2651593, AB_2651592

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for E4BP4 (NFIL3) Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support